SEOUL, Jan. 9 (Korea Bizwire) — SK Inc., the holding company of South Korea’s No. 3 conglomerate SK Group, said Sunday that it has invested US$350 million in the Center for Breakthrough Medicines (CBM), becoming the second-largest stakeholder of the U.S. gene therapy company. SK said the investment deal with the Philadelphia-based contract development manufacturing [...]
SEOUL, Nov. 16 (Korea Bizwire) — SK Inc., the holding company of South Korea’s No. 3 conglomerate SK Group, said Tuesday it is in the final talks to invest in a U.S. gene therapy company, in its latest move to expand its foothold in global biopharmaceuticals. SK said it plans to sign a formal deal [...]
MIAMI, Oct. 19 (Korea Bizwire) — Ambulero Inc., a biotechnology company (“Ambulero” or the “Company”) developing new cell and gene therapy treatments for patients suffering from severe vascular disease, today announced that the U.S. FDA’s Office For Orphan Products Development (OOPD) granted the company’s request for orphan drug status for its gene therapy candidate, AMB-301, [...]
SEOUL, Aug. 6 (Korea Bizwire) — A state-run research institute with a specialty in weapons development is now developing a cure for COVID-19. South Korea’s Agency for Defense Development (ADD) announced on Wednesday that it confirmed the effectiveness of its newly-developed COVID-19 siRNA gene therapy treatment after conducting animal tests. The new treatment is designed [...]
SEOUL, July 16 (Korea Bizwire) — New government regulations will require South Korean biotech companies to track and monitor patients who are injected with stem cells or gene therapy treatments. According to the Ministry of Food and Drug Safety on Wednesday, the Advanced Regenerative Bio Act, enacted to strengthen the safety management of advanced regenerative [...]
SEOUL, May 28 (Korea Bizwire) — South Korea’s drug authorities on Tuesday canceled the license for the gene therapy drug Invossa for the mislabeling and the false reporting of an ingredient used, sending a shock to patients and the country’s pharmaceuticals sector. The Ministry of Food and Drug Safety’s move came after the manufacturer, Kolon [...]
TOKYO, Apr. 5 (Korea Bizwire) — AnGes, Inc., a biopharmaceutical company focused on developing innovative gene-based medicines for treating serious diseases, announced today that they have obtained conditional approval (“Approval with Conditions and Time Limit”) from the Japanese Ministry of Health, Labour and Welfare (MHLW) for HGF plasmid to treat patients with critical limb ischemia [...]
NEW YORK, Feb. 9, 2015 (Korea Bizwire) – A market for gene therapy exceeding $13 billion could be possible by 2025 if the technologies show success in the current trials underway. Gene therapy involves modification of genes instead of using a surgical method or chemical drug product. The healthcare market researcher revealed its finding in The [...]